Dave with his daughter Davina on the outskirts of Edinburgh. He was two thirds of the way from Land’s End to John O’Groats on a sponsored cycle to raise funds for brain research supported by the Neurosciences Foundation. £3,000 was raised to support stroke research.
A stroke study
During visits to a Care Home to be with a friend who had been left extremely disabled as a result of a stroke caused by a blockage in blood supply to the brain, Dave was made only too well aware of the need for research that might help in the future. He decided that his second mad cycle should be from Land’s End to John O’Groats and that the proceeds should go towards supporting a stroke project. Here is Dave with his daughter Davina on the outskirts of Edinburgh. He was two thirds of the way there and beginning to get used to the 100 miles a day routine. Around £3,000 was raised to support stroke research. Added to other donations this enabled the Foundation to support a project led by Professor Keith Muir at the Queen Elizabeth Hospital. The aim was to see if the time window for use of clot busting drugs could be extended beyond the currently accepted 4.5 hours, possibly to as long as 24 hours. The finding suggested that this might well be the case and this preliminary data helped the research team to secure funds for a much larger study.
A brain tumour study
Dave is one of our Trustees. A colleague, Dr Aled Evans, died from an aggressive Glioma when still in the prime of his career. In his memory, Dave decided to attempt a sponsored cycle from the Channel to the Mediterranean organised by Sport Ecosse. This managed to raise around £3,000 to help to support brain cancer research. Along with other donations the Foundation was able to offer £35K towards funding a studentship based at the Cancer Research Centre at the Beatson Laboratories in Glasgow. The successful applicant, Maria, is now nearing the end of her project. She has learned a great deal from the world experts who are supervising her, and her project is helping to shed some light on the mechanisms of what are called PARP inhibitors that are used in the treatment of glioma.